-
2:00PM - 2:15PM EST
Welcome and Introductions
Alexander Krupnick, University of Maryland Medical System
Dr. Krupnick is the chief of thoracic surgery at the University of Maryland School of Medicine with an academic and clinical focus dedicated to the care of patients with end-stage lung failure and oncologic disease. He provides a full range of thoracic surgery services, including minimally invasive lung and esophageal resections, on the University of Maryland Medical School main campus as as affiliated hospitals. His laboratory has made seminal contributions toward the understanding lung transplant immunology, including the development of the world’s first model of vascularized orthotopic lung transplantation in the mouse (PMC3848695). He has also described numerous mechanistic aspects of lung allograft tolerance and rejection including the role of CD8+ T cells and eosinophils in mediating lung allograft tolerance (PMC3938255, PMC6629120). In addition to work on transplantation my laboratory has focused extensive efforts on understanding and reversing immunological dysfunction associated with cancer. His laboratory has made contributions in describing the role of natural killer cells in controlling lung cancer development and progression (PMID: 22751136), as well as advancing the understanding of immunological factors that limit natural killer cell function in malignancies (PMID: 30381460, 28123874). Based this understanding he has developed a rationally designed retargeted cytokine to activate natural killer cells and CD8+ cytotoxic lymphocytes (PMID: 27650575). These efforts are now being advanced toward human applications with an IND application in progress, GMP drug production initiated, and clinical trials planned for summer of 2022. -
2:15PM - 2:45PM EST
Critical History and Importance of Surgical Research, Platform for Developing a Research Program in Modern Day of Academic Medicine
Alexander Krupnick, University of Maryland Medical System
Dr. Krupnick is the chief of thoracic surgery at the University of Maryland School of Medicine with an academic and clinical focus dedicated to the care of patients with end-stage lung failure and oncologic disease. He provides a full range of thoracic surgery services, including minimally invasive lung and esophageal resections, on the University of Maryland Medical School main campus as as affiliated hospitals. His laboratory has made seminal contributions toward the understanding lung transplant immunology, including the development of the world’s first model of vascularized orthotopic lung transplantation in the mouse (PMC3848695). He has also described numerous mechanistic aspects of lung allograft tolerance and rejection including the role of CD8+ T cells and eosinophils in mediating lung allograft tolerance (PMC3938255, PMC6629120). In addition to work on transplantation my laboratory has focused extensive efforts on understanding and reversing immunological dysfunction associated with cancer. His laboratory has made contributions in describing the role of natural killer cells in controlling lung cancer development and progression (PMID: 22751136), as well as advancing the understanding of immunological factors that limit natural killer cell function in malignancies (PMID: 30381460, 28123874). Based this understanding he has developed a rationally designed retargeted cytokine to activate natural killer cells and CD8+ cytotoxic lymphocytes (PMID: 27650575). These efforts are now being advanced toward human applications with an IND application in progress, GMP drug production initiated, and clinical trials planned for summer of 2022. -
3:00PM - 8:00PM EST
Session I – Sources of Surgical Funding
Matthew Bott, Memorial Sloan-Kettering Cancer Center
Dr. Bott is a thoracic surgeon at Memorial Sloan-Kettering Cancer Center. After completing an undergraduate degree at Duke University, he went on to medical school at the University of Virginia and then a general surgery residency at New York Presbyterian Hospital - Weill Cornell Medical Center. During his residency he took part in a research fellowship at MSK which investigated genomic pertubations in malignant pleural mesothelioma. Following his completion of cardiothoracic surgery fellowship at Washington University in St. Louis in 2015, he joined the faculty of MSKCC and currently has a practice focused on thoracic surgical oncology. He is currently the surgical director of endobronchial therapies and co-leads MSK's robotic bronchoscopy program. He also has an active basic and translational research program which explores cellular responses to therapy in lung cancer.
-
8:00PM - 9:00PM EST
-
9:00PM - 10:00PM EST
Cocktail Hour with Meet and Greet